Small Molecule Helios Degraders for Cancer Treatment
Summary
The European Patent Office published patent application EP4051386A1 for Dana-Farber Cancer Institute's small molecule Helios degrader compounds and methods for treating cancer. The patent application covers A61P 35/00 classifications and 12 different heterocyclic compound formulations under the C07D chemical series. The patent designates all 39 European Patent Convention member states.
What changed
The EPO published patent application EP4051386A1 granting Dana-Farber Cancer Institute exclusive rights to small molecule Helios degrader compounds for cancer treatment. The patent covers multiple chemical compound formulations (C07D series) and their use in treating cancers classified under A61P 35/00.
Pharmaceutical and biotech companies developing targeted cancer therapies should review this patent for potential freedom-to-operate concerns. The broad heterocyclic compound coverage and multiple designated states create potential licensing or collaboration opportunities with Dana-Farber for companies seeking access to Helios degrader technology.
What to do next
- Review patent claims for freedom-to-operate analysis
- Monitor for related patent family publications in other jurisdictions
- Assess potential licensing or collaboration opportunities with Dana-Farber
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE
Publication EP4051386A1 Kind: A1 Apr 01, 2026
Applicants
Dana-Farber Cancer Institute, Inc.
Inventors
GRAY, Nathanael S., LIU, Hu, ZHANG, Tinghu, JONES, Lyn Howard, CHE, Jianwei
IPC Classifications
C07D 405/14 20060101AFI20240417BHEP C07D 401/14 20060101ALI20240417BHEP A61P 35/00 20060101ALI20240417BHEP C07D 413/14 20060101ALI20240417BHEP C07D 417/14 20060101ALI20240417BHEP C07D 419/14 20060101ALI20240417BHEP C07D 487/10 20060101ALI20240417BHEP C07D 491/044 20060101ALI20240417BHEP C07D 498/08 20060101ALI20240417BHEP C07D 491/107 20060101ALI20240417BHEP C07D 471/04 20060101ALI20240417BHEP C07D 487/08 20060101ALI20240417BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.